Exanta

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2002-2007
051020022007

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2004
2004
Drug Name: Exanta (ximelagatran) 36 mg bid oral formulation Indication(s): reduction of risk of stroke or systemic embolic events… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2004
2004
INTRODUCTION The effect of the oral direct thrombin inhibitor (DTI) ximelagatran (Exanta, AstraZeneca) on the endogenous thrombin… (More)
Is this relevant?
Review
2004
Review
2004
Ximelagatran (Exanta, AstraZeneca) is a novel oral direct thrombin inhibitor that inhibits the final step in the coagulation… (More)
Is this relevant?
Review
2004
Review
2004
Patients who undergo orthopaedic surgery are at substantially increased risk for venous thromboembolic events. These include… (More)
Is this relevant?
2003
2003
  • Owen Glynn
  • International journal of clinical practice
  • 2003
The phase III trial EXPRESS was a randomised, double-blind comparison of two anticoagulant therapies used as prophylaxis against… (More)
Is this relevant?
2003
2003
Two new classes of anticoagulants in development at the present time [anti-factor Xa and anti-factor IIa (direct antithrombin… (More)
Is this relevant?
Review
2003
Review
2003
Ximelagatran (Exanta, AstraZeneca) is a novel, oral direct thrombin inhibitor (oral DTI) that is rapidly converted to melagatran… (More)
Is this relevant?
Review
2003
Review
2003
There are many well-known drawbacks associated with the currently used antithrombotic agents, warfarin, heparin, and low… (More)
Is this relevant?
Review
2003
Review
2003
The oral direct thrombin inhibitor (oral DTI) ximelagatran (Exanta, AstraZeneca) is rapidly absorbed and bioconverted to its… (More)
Is this relevant?